Scarica l'app Stockscreener
13.50
0.74%
-0.10
Precedente Chiudi:
$13.60
Aprire:
$13.5
Volume 24 ore:
14,446
Relative Volume:
0.51
Capitalizzazione di mercato:
$32.84M
Reddito:
$5.02M
Utile/perdita netta:
$-20.25M
Rapporto P/E:
-56.25
EPS:
-0.24
Flusso di cassa netto:
$-19.08M
1 W Prestazione:
-3.78%
1M Prestazione:
-7.28%
6M Prestazione:
-47.06%
1 anno Prestazione:
+3,379%
Intervallo 1D:
$13.19
$13.65
Intervallo di 1 settimana:
$13.19
$15.40
Portata 52W:
$0.35
$30.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Nome
Vtv Therapeutics Inc
Settore
Industria
Telefono
336-841-0300
Indirizzo
3980 PREMIER DR, HIGH POINT, NC
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-30 | Iniziato | H.C. Wainwright | Buy |
| 2018-04-10 | Downgrade | Stifel | Buy → Hold |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Iniziato | Northland Capital | Outperform |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2015-09-04 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-24 | Iniziato | Piper Jaffray | Overweight |
| 2015-08-24 | Iniziato | Stifel | Buy |
Mostra tutto
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
(VTVT) Investment Analysis - Stock Traders Daily
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
How the (VTVT) price action is used to our Advantage - Stock Traders Daily
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
VTv Therapeutics : Termination of Material Agreement Form 8 K - Marketscreener.com
VTv Therapeutics: Q2 Earnings Snapshot - Barchart
Alzheimer's disease Market Size in the 7MM was ~USD 3,500 Million in 2022 | DelveInsight - openPR
Trading (VTVT) With Integrated Risk Controls - Stock Traders Daily
Objective long/short (VTVT) Report - Stock Traders Daily
Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight - Barchart
Alzheimer’s Disease Treatment Market Trends As Discussed In New Market Research Report - WhaTech
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Views of Wall Street’s Leading Experts on Volcon Inc - SETE News
Travere Therapeutics Inc (TVTX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Valvoline Inc [VVV] Insider Activity: An Update for Investors - Knox Daily
Ventyx Biosciences Inc (VTYX) looking to reclaim success with recent performance - SETE News
What is going on with VCHA? Cancellations, member hiatus and more - MSN
Vital Energy Inc. (VTLE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Vanguard Total Corporate Bond Fund (NASDAQ:VTC) Reaches New 52-Week High at $79.92 - MarketBeat
VTYX overperforms with a 2.18 increase in share price - US Post News
VTLE’s latest rating updates from top analysts. - Knox Daily
TV’s 2023 Market Dance: Down -32.71% – Time to Invest? - The InvestChronicle
Texas Permanent School Fund Corp Sells 9,072 Shares of Veralto Co. (NYSE:VLTO) - Defense World
Learn to Evaluate (VTVT) using the Charts - Stock Traders Daily
Travere Therapeutics Inc [TVTX] Shares Rise 2.94 % on Thursday - Knox Daily
Neighbors concerned with proposed hospital in Webster Groves - KTVI Fox 2 St. Louis
When (VTVT) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate - Yahoo Finance
Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Rises By 45.9% - Defense World
VTVT (vTv Therapeutics) Operating Cash Flow per Share : $-6.50 (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Free Cash Flow : $-21.81 Mil (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Change In Receivables : $-0.20 Mil (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Cyclically Adjusted Book per Share : $-228.01 (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Short-Term Capital Lease Obligation : $0.18 Mil (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Revenue per Share : $0.24 (TTM As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Ending Cash Position : $45.53 Mil (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Net Income From Continuing Operatio - GuruFocus.com
VTVT (vTv Therapeutics) Cash from Discontinued Operating Ac - GuruFocus.com
VTVT (vTv Therapeutics) GF Value Rank : 1 (As of Aug. 15, 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
VTVT (vTv Therapeutics) Liabilities-to-Assets : 0.56 (As of Jun. 2024) - GuruFocus.com
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Where are the Opportunities in (VTVT) - Stock Traders Daily
FDA puts High Point company's type-1 diabetes clinical trial on hold - Winston-Salem Journal
Dow Edges Lower; Ventyx Biosciences Shares Plummet - Benzinga
FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks - AOL
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump - Benzinga
Nasdaq Gains 1%; McDonald's Posts Downbeat Results - Benzinga
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today? - InvestorPlace
Vtv Therapeutics Inc Azioni (VTVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.47%
6.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):